The Girona Biomedical Research Institute (IDIBGI) has named its Proteomics room ‘Sala Bosch Aymerich’, in gratitude and recognition of the Bosch Aymerich Foundation (FBA) for its support in the search for new therapeutic targets against cancer. The Bosch Aymerich Foundation has been fundamental to the research of the Chromosomal Replication group at IDIBGI, led by Dr. Jordi Frigola: ‘the Bosch and Aymerich Foundation has played a key role in our project, with which we are seeking and developing new ways to inhibit tumour progression, with the main aim of reducing the toxicity of current treatments’, remarks Dr. Frigola.
The Chromosomal Replication group's project aims to develop new specific and selective inhibitors of the early stages of DNA replication. This is a step that occurs before the cell divides, and stopping it would prevent tumour proliferation.
This approach is doubly innovative because it targets the early steps of DNA synthesis and does so in a targeted and selective manner, unlike current treatments with radiotherapy and classical chemotherapy. Ultimately, these new inhibitors will reduce the toxicity of current therapies and improve the quality of life of many cancer patients.
‘Undoubtedly, the impetus and support of the Bosch Aymerich Foundation has been decisive for us to be in the pre-clinical phase of this new anti-tumour treatment’, stresses Dr. Frigola, who adds: ‘The FBA believed in the project from day one. An immense part of the success and progress of the project has been possible thanks to their support throughout all these years.
Due to its importance in the project and as a sign of gratitude, IDIBGI wanted to name its first nominal room the Bosch Aymerich Room. The Bosch Aymerich Room at IDIBGI is used by the Chromosome Replication research group and contains equipment for proteomic studies, which allow the different proteins involved in the copying of genetic material to be analysed at the molecular level.
This morning the representative of the board of trustees and member of the standing committee of the Bosch Aymerich Foundation, Àngel Dutras, and the manager of FBA, Rafael Faus, visited IDIBGI and the Proteomics Room. They were received by the director of IDIBGI, Dr. Marga Nadal, the manager, Anna Ribas, together with all the members of the Chromosomal Replication research group, and the head of Patronage, Ferran Pedró.
About the Bosch Aymerich Foundation
The Bosch Aymerich Foundation was created by Mr. Josep Mª Bosch Aymerich Dr. Architect-Dr. Engineer and his wife, Mrs. Mª Rosa Escarpenter Fargas, in 1996. The Foundation aims to create, promote and develop activities of general interest, preferably within the territory of Catalonia, related to: the world of Arts, Culture, Science, Sport, Health, promoting the quality of life of the elderly, training and / or education in the leisure of Youth, Architecture, Urbanism. Since 2016 the FBA has collaborated in more than 150 projects in the fields of action established by its founder Josep Ma. Aymerich.
About IDIBGI
The Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI) carries out translational research to improve health and care of people. IDIBGI is organised into 25 research groups distributed in five scientific areas (Cardiovascular and Respiratory, Metabolism and Inflammation, Neurosciences, Oncohematology and Mental Health) that bring together more than 400 people, including health professionals and basic researchers, in the region of Girona.
The IDIBGI is a public foundation made up of the Generalitat de Catalunya, the Catalan Health Institute (ICS) Girona, the Institute of Health Care (IAS), the Catalan Institute of Oncology (ICO) Girona, and the University of Girona. IDIBGI is a CERCA centre (Research Centres of Catalonia) since 2005.
